Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - oxantel embonate; pyrantel embonate; praziquantel - oral tablet - oxantel embonate anthelmintic active 542.0 mg/tb; pyrantel embonate anthelmintic active 143.0 mg/tb; praziquantel anthelmintic active 50.0 mg/tb - parasiticides - dog | bitch | castrate | puppy - false hydatid tapeworm-taenia hydatigena | hookworm - ancylostoma braziliense | hookworm - ancylostoma caninum | hookworm - uncinaria stenocephala | hydatid tapeworm | roundworm - toxascaris leonina | roundworm - toxocara canis | sheep measles tapeworm - taenia ovis | tapeworm - dipylidium caninum | tapeworm - taenia pisiformis | whipworm - trichuris vulpis | ascarid | human intestinal roundworm

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - albendazole - oral solution/suspension - albendazole carbamate-benzimidazole active 19.0 g/l - parasiticides - goat | lamb | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - barber's pole worm-haemonchus contortus | black scour worm - trichostrongylus spp. | hookworm - bunostomum trigonocephalum | large bowel worm - o. venulosum | large lungworm - dictyocaulus filaria | large mouthed bowel worm | liver fluke | nodule worm - o. columbianum | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | tapeworm - moniezia spp. | thin necked intestinal worm | hair worm | intestinal hair worm | small hair worm | tapeworm - heads/segments | teladorsagia

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - milbemycin oxime; praziquantel - oral tablet - milbemycin oxime antibiotic active 16.0 mg; praziquantel anthelmintic active 40.0 mg - parasiticides - cat - over 2 kg - hookworm - ancylostoma tubaeforme | roundworm - toxascaris leonina | roundworm - toxocara cati | tapeworm - dipylidium caninum | tapeworm - taenia spp. | ascarid | human intestinal roundworm | toxocara mystax

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - milbemycin oxime; praziquantel - oral tablet - milbemycin oxime antibiotic active 4.0 mg; praziquantel anthelmintic active 10.0 mg - parasiticides - cat - small | kitten | young cat - hookworm - ancylostoma tubaeforme | roundworm - toxascaris leonina | roundworm - toxocara cati | tapeworm - dipylidium caninum | tapeworm - taenia spp. | ascarid | human intestinal roundworm | toxocara mystax

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - pyrantel embonate; praziquantel - oral tablet - pyrantel embonate anthelmintic active 100.0 mg/tb; praziquantel anthelmintic active 25.0 mg/tb - parasiticides - cat | kitten | cat - queen | cat - tom | kitten | young cat - hookworm - ancylostoma braziliense | hookworm - ancylostoma tubaeforme | hookworm - uncinaria stenocephala | roundworm - toxascaris leonina | roundworm - toxocara cati | tapeworm - dipylidium caninum | tapeworm - taenia taeniaeformis | ascarid | human intestinal roundworm | toxocara mystax

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - levamisole; niclosamide - oral tablet - levamisole anthelmintic active 41.8 mg/tb; niclosamide anthelmintic active 1000.0 mg/tb - parasiticides - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - hookworm | roundworm | tapeworm - excluding hydatid | ancylostoma braziliense | ancylostoma caninum | toxocara mystax | toxocara spp. | uncinaria stenocephala

Australia - angielski - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 150 mg - injection, powder for - excipient ingredients: histidine hydrochloride; polysorbate 20; histidine; trehalose dihydrate - early breast cancer,indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer,indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant therapy.,metastatic breast cancer,indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,advanced gastric cancer,indicated in combination with cisplatin and either capecitabine or 5-fu for the treatmen

Australia - angielski - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 150 mg - injection, powder for - excipient ingredients: histidine hydrochloride; polysorbate 20; histidine; trehalose dihydrate - early breast cancer,indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer,indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant therapy.,metastatic breast cancer,indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,advanced gastric cancer,indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastrooesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 150 mg - injection, powder for - excipient ingredients: histidine hydrochloride; polysorbate 20; histidine; trehalose dihydrate - early breast cancer,indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer,indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant therapy.,metastatic breast cancer,indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,advanced gastric cancer,indicated in combination with cisplatin and either capecitabine or 5-fu for the treatmen

Australia - angielski - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: histidine hydrochloride; histidine; polysorbate 20; trehalose dihydrate - early breast cancer herzuma? is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer herzuma? is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herzuma?.,metastatic breast cancer herzuma? is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormonereceptor positive metastatic breast cancer.,advanced gastric cancer herzuma? is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro- oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.